

Tracy M Frech

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5015715/publications.pdf>

Version: 2024-02-01

114
papers

4,034
citations

185998

28
h-index

128067

60
g-index

116
all docs

116
docs citations

116
times ranked

3912
citing authors

#	ARTICLE	IF	CITATIONS
1	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 708-719.	5.2	754
2	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. <i>Lancet</i> , 2016, 387, 2630-2640.	6.3	505
3	Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 212-220.	0.5	236
4	Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. <i>Autoimmunity Reviews</i> , 2020, 19, 102458.	2.5	231
5	ImmunoChip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	2.6	182
6	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 125-136.	2.9	163
7	Survival and Predictors of Mortality in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry. <i>Arthritis Care and Research</i> , 2014, 66, 489-495.	1.5	132
8	Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 379-386.	0.5	97
9	Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1335-1342.	0.5	82
10	Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). <i>Chest</i> , 2018, 154, 862-871.	0.4	72
11	Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?. <i>Frontiers in Immunology</i> , 2018, 9, 2045.	2.2	67
12	Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1350-1360.	2.9	67
13	Antinuclear antibody-negative systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 680-686.	1.6	60
14	Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2018, 70, 1373-1384.	1.5	54
15	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. <i>Rheumatology</i> , 2018, 57, 1623-1631.	0.9	53
16	Prevalence and correlates of sleep disturbance in systemic sclerosis—results from the UCLA scleroderma quality of life study. <i>Rheumatology</i> , 2011, 50, 1280-1287.	0.9	48
17	Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/ distention. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S22-5.	0.4	46
18	Heritability of vasculopathy, autoimmune disease, and fibrosis in systemic sclerosis: A population-based study. <i>Arthritis and Rheumatism</i> , 2010, 62, 2109-2116.	6.7	42

#	ARTICLE	IF	CITATIONS
19	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019, 71, 964-971.	2.9	41
20	Gastrointestinal and Hepatic Disease in Systemic Sclerosis. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, 15-28.	0.8	39
21	Vascular Leak Is a Central Feature in the Pathogenesis of Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2012, 39, 1385-1391.	1.0	36
22	Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1892-1896.	2.9	36
23	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e743-e753.	2.2	34
24	Systemic sclerosis induces pronounced peripheral vascular dysfunction characterized by blunted peripheral vasoreactivity and endothelial dysfunction. <i>Clinical Rheumatology</i> , 2015, 34, 905-913.	1.0	33
25	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC vascular working group report. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 249-252.	1.0	33
26	Validation of the Self-Efficacy for Managing Chronic Disease Scale: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2016, 68, 1195-1200.	1.5	31
27	Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. <i>Arthritis Research and Therapy</i> , 2021, 23, 170.	1.6	30
28	Treatment of early diffuse systemic sclerosis skin disease. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 166-71.	0.4	30
29	The Critical Need for Accurately Defining Digital Ulcers in Scleroderma. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 69-71.	1.0	29
30	The utility of nutraceuticals in the treatment of osteoarthritis. <i>Current Rheumatology Reports</i> , 2007, 9, 25-30.	2.1	28
31	Low-Dose Naltrexone for Pruritus in Systemic Sclerosis. <i>International Journal of Rheumatology</i> , 2011, 2011, 1-5.	0.9	28
32	Nutritional status and gastrointestinal symptoms in systemic sclerosis patients. <i>Clinical Nutrition</i> , 2013, 32, 130-135.	2.3	27
33	Automated Measurement of Microvascular Function Reveals Dysfunction in Systemic Sclerosis: A Cross-sectional Study. <i>Journal of Rheumatology</i> , 2017, 44, 1603-1611.	1.0	26
34	Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 42-49.	1.0	25
35	Multicenter Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2020, 72, 723-733.	1.5	25
36	Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. <i>Journal of Psychosomatic Research</i> , 2020, 139, 110262.	1.2	25

#	ARTICLE	IF	CITATIONS
37	Factors Influencing Raynaud Condition Score Diary Outcomes in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2019, 46, 1326-1334.	1.0	24
38	Evolving Symptom Characteristics of Raynaud's Phenomenon in Systemic Sclerosis and Their Association With Physician and Patient-Reported Assessments of Disease Severity. <i>Arthritis Care and Research</i> , 2019, 71, 1119-1126.	1.5	23
39	A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101707.	1.4	22
40	A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. <i>Arthritis Research and Therapy</i> , 2019, 21, 202.	1.6	21
41	Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 1005-1013.	2.9	21
42	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. <i>Journal of Psychosomatic Research</i> , 2020, 135, 110132.	1.2	21
43	Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. <i>Rheumatology</i> , 2021, 60, 1410-1418.	0.9	20
44	Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: An introduction by The Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS). <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101695.	1.4	19
45	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. <i>Arthritis Research and Therapy</i> , 2016, 18, 20.	1.6	18
46	Peripheral neuropathy: a complication of systemic sclerosis. <i>Clinical Rheumatology</i> , 2013, 32, 885-888.	1.0	17
47	Autophagy is a key feature in the pathogenesis of systemic sclerosis. <i>Rheumatology International</i> , 2014, 34, 435-439.	1.5	17
48	The Recurrence of Digital Ulcers in Patients with Systemic Sclerosis after Discontinuation of Oral Treprostinil. <i>Journal of Rheumatology</i> , 2016, 43, 1665-1671.	1.0	17
49	Review of local wound management for scleroderma-associated digital ulcers. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 66-70.	1.0	17
50	Primary care assessment of capillaroscopy abnormalities in patients with Raynaud's phenomenon. <i>Clinical Rheumatology</i> , 2015, 34, 2135-2140.	1.0	16
51	Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort. <i>Journal of Rheumatology</i> , 2017, 44, 791-794.	1.0	14
52	Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018, 57, 152-157.	0.9	13
53	An interim report of the Scleroderma Clinical Trials Consortium working groups. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 17-27.	1.0	13
54	Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease - Scleroderma Clinical Trials Consortium. <i>Journal of Rheumatology</i> , 2019, 46, 78-84.	1.0	13

#	ARTICLE	IF	CITATIONS
55	Identifying barriers and facilitators to physical activity for people with scleroderma: a nominal group technique study. <i>Disability and Rehabilitation</i> , 2021, 43, 3339-3346.	0.9	12
56	The Prevalence and Clinical Correlates of an Auscultatory Gap in Systemic Sclerosis Patients. <i>International Journal of Rheumatology</i> , 2012, 2012, 1-4.	0.9	11
57	Exercise-induced brachial artery blood flow and vascular function is impaired in systemic sclerosis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 311, H1375-H1381.	1.5	11
58	Patient experiences of digital ulcer development and evolution in systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 2156-2158.	0.9	11
59	Informatics can identify systemic sclerosis (SSc) patients at risk for scleroderma renal crisis. <i>Computers in Biology and Medicine</i> , 2014, 53, 203-205.	3.9	10
60	Sublingual Abnormalities in Systemic Sclerosis. <i>Journal of Clinical Rheumatology</i> , 2016, 22, 19-21.	0.5	10
61	Systemic sclerosis: The need for structured care. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 3-21.	1.4	10
62	Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. <i>Journal of Psychosomatic Research</i> , 2021, 140, 110314.	1.2	9
63	Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study. <i>Lancet Rheumatology</i> , The, 2021, 3, e844-e854.	2.2	9
64	Expanding Personalized, Data-Driven Dermatology: Leveraging Digital Health Technology and Machine Learning to Improve Patient Outcomes. <i>JID Innovations</i> , 2022, 2, 100105.	1.2	9
65	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1646-1652.	1.5	8
66	Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry. <i>Clinical Rheumatology</i> , 2020, 39, 93-102.	1.0	8
67	Protective role of interleukin-6 in systemic sclerosis gastrointestinal tract involvement: case report and review of the literature. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S179-81.	0.4	8
68	The Vascular Microenvironment and Systemic Sclerosis. <i>International Journal of Rheumatology</i> , 2010, 2010, 1-6.	0.9	7
69	Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report. <i>Journal of Medical Case Reports</i> , 2015, 9, 136.	0.4	7
70	Does hand involvement in systemic sclerosis limit completion of patient-reported outcome measures?. <i>Clinical Rheumatology</i> , 2021, 40, 965-971.	1.0	7
71	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. <i>JMIR Research Protocols</i> , 2020, 9, e16799.	0.5	7
72	Patient participation in patient-reported outcome instrument development in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 184-192.	0.4	7

#	ARTICLE	IF	CITATIONS
73	Acute oral tetrahydrobiopterin administration ameliorates endothelial dysfunction in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 167-172.	0.4	6
74	Understanding itch in systemic sclerosis in order to improve patient quality of life. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 81-8.	0.4	6
75	Does sublingual microscopy correlate with nailfold videocapillaroscopy in systemic sclerosis?. <i>Clinical Rheumatology</i> , 2021, 40, 2263-2266.	1.0	5
76	Non-invasive digital thermal monitoring and flow-mediated dilation in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 97-101.	0.4	5
77	A novel transition clinic structure for adolescent and young adult patients with childhood onset rheumatic disease improves transition outcomes. <i>Pediatric Rheumatology</i> , 2021, 19, 164.	0.9	5
78	Results from an American pilot survey among Scleroderma Clinical Trials Consortium members on capillaroscopy use and how to best implement nailfold capillaroscopy training. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 151.	0.4	5
79	Attenuated nitric oxide bioavailability in systemic sclerosis: Evidence from the novel assessment of passive leg movement. <i>Experimental Physiology</i> , 2018, 103, 1412-1424.	0.9	4
80	Presence of Antitopoisomerase I Antibody Alone May Not Be Sufficient for the Diagnosis of Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2019, 46, 440-442.	1.0	4
81	Small intestinal bacterial overgrowth in systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 33-39.	1.0	4
82	Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patient-centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2022, 74, 1300-1310.	1.5	4
83	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. <i>Trials</i> , 2021, 22, 856.	0.7	4
84	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. <i>Body Image</i> , 2017, 20, 99-106.	1.9	3
85	Understanding empirical therapeutics in systemic sclerosis gastrointestinal tract disease. <i>Rheumatology</i> , 2017, 56, 176-177.	0.9	3
86	Gut Disease in Systemic Sclerosis—New Approaches to Common Problems. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 11-19.	0.6	3
87	A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 1505-1513.	0.9	3
88	Big data in systemic sclerosis: Great potential for the future. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 172-177.	1.0	3
89	Effect of Coping Strategies on Patient and Physician Perceptions of Disease Severity and Disability in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021, 48, 1569-1573.	1.0	3
90	Implications of endothelial shear stress on systemic sclerosis vasculopathy and treatment. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 175-182.	0.4	3

#	ARTICLE	IF	CITATIONS
91	Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multi-center US-based longitudinal registry. <i>International Journal of Rheumatic Diseases</i> , 2022, 25, 163-174.	0.9	3
92	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. <i>Pilot and Feasibility Studies</i> , 2022, 8, 45.	0.5	3
93	Parental Influence on Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2015, 67, 310-312.	1.5	2
94	Eosinophilic Esophagitis in Two Patients with Systemic Sclerosis. <i>Case Reports in Rheumatology</i> , 2016, 2016, 1-5.	0.2	2
95	A normal diffusing capacity of the lungs for carbon monoxide is rare in incidental pulmonary arterial hypertension in systemic sclerosis: Data from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma cohort. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 237-241.	1.0	2
96	Raynaud Phenomenon in Systemic Sclerosis: Does Digital Thermal Monitoring Correlate to Specific Nailfold Videocapillaroscopy Abnormalities?. <i>Journal of Rheumatology</i> , 2021, 48, 247-250.	1.0	2
97	The frequency of Raynaud's phenomenon, very early diagnosis of systemic sclerosis, and systemic sclerosis in a large Veteran Health Administration database. <i>BMC Rheumatology</i> , 2021, 5, 42.	0.6	2
98	Treatment of ankylosing spondylitis: focus on etanercept. <i>Biologics: Targets and Therapy</i> , 2007, 1, 45-51.	3.0	2
99	Chronic Multiorgan Rare Disease: The Role of the Nurse Practitioner as a Leader of the Healthcare Team. <i>Journal of Medical Practice Management</i> , 2017, 32, 413-416.	0.1	2
100	Tetrahydrobiopterin Administration Augments Exercise-Induced Hyperemia and Endothelial Function in Patients With Systemic Sclerosis. <i>Frontiers in Medicine</i> , 2021, 8, 791689.	1.2	2
101	Computed Tomography of the Chest to Screen for Interstitial Lung Disease in Patients With Systemic Sclerosis at Expert Scleroderma Centers in the United States. <i>ACR Open Rheumatology</i> , 2022, 4, 596-602.	0.9	2
102	Bone Mineral Density in Navajo Men and Women and Comparison to Non-Hispanic Whites from NHANES (2005-2008). <i>Journal of Health Care for the Poor and Underserved</i> , 2016, 27, 644-662.	0.4	1
103	Treatment efficacy in secondary Raynaud's phenomenon. <i>Lancet Rheumatology</i> , The, 2020, 2, e132.	2.2	1
104	Pulmonary Vascular Resistance in Systemic Sclerosis Patients With Pulmonary Hypertension. <i>Chest</i> , 2011, 140, 717A.	0.4	0
105	Implementation of an advance directive focus in a Chronic Multi-Organ Rare Disease Clinic. <i>Annals of Palliative Medicine</i> , 2017, 6, S206-S208.	0.5	0
106	The evaluation and management of gastrointestinal manifestations of systemic sclerosis. <i>Rheumatology</i> , 2018, 57, .	0.9	0
107	Pauling and Frech reply. <i>Journal of Rheumatology</i> , 2019, 46, 1544-1545.	1.0	0
108	Dr. Tebo, et al. reply. <i>Journal of Rheumatology</i> , 2019, 46, 1547.2-1547.	1.0	0

#	ARTICLE	IF	CITATIONS
109	Reply. Arthritis and Rheumatology, 2021, 73, 716-717.	2.9	0
110	Clinical Bedside Tools to Assess Systemic Sclerosis Vasculopathy: Can Digital Thermal Monitoring and Sublingual Microscopy Identify Patients With Digital Ulcers?. Journal of Rheumatology, 2021, 48, 1566-1568.	1.0	0
111	Routine Chest Radiographs Are Not Necessary Following Ultrasound Guided Right Heart Catheterization. Chest, 2011, 140, 718A.	0.4	0
112	The Impact of Acute Tetrahydrobiopterin Administration on Plasma Adropin Concentration in Patients with Systemic Sclerosis. FASEB Journal, 2018, 32, 902.20.	0.2	0
113	Oesophageal disease in systemic sclerosis: does heritability play a role?. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 86-88.	0.4	0
114	Is it Still "Idiopathic"? Features of Autoimmunity in IPAH. American Journal of Respiratory and Critical Care Medicine, 2022, , .	2.5	0